{"disease":{"id":"bullous-pemphigoid-bp","name":"bullous pemphigoid bp"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07210554","title":"Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Chengdu Kangnuoxing Biopharma,Inc.","has_results":false},{"nct_id":"NCT06723106","title":"Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":144,"lead_sponsor_name":"Chugai Pharmaceutical","has_results":false},{"nct_id":"NCT06371417","title":"Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":144,"lead_sponsor_name":"Chugai Pharmaceutical","has_results":false},{"nct_id":"NCT07188402","title":"Prevalence of Sleep Disturbances in Bullous Pemphigoid Patients.","phase":"","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT02502903","title":"Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Bioverativ, a Sanofi company","has_results":false},{"nct_id":"NCT04035733","title":"rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"AKARI Therapeutics","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}